A pharmaceutical composition for reducing the harm of ionizing radiation

Abstract

The present invention relates to a pharmaceutical composition for reducing the harm of ionizing radiation, and belongs to the technical field of traditional Chinese medicine. The pharmaceutical composition is composed of the following components by weight: 570-630 parts of Radix Rehmanniae Preparata, 4-14 parts of crystal orchioides, 17-27 parts of nesitose, 60-80 parts of Radix Ophiopogonis polysaccharides, 75-95 parts of Poria cocos polysaccharides, 1-5 parts of pachymic acid, and 1-3 parts of schisandrae. The pharmaceutical composition of the present invention has the advantages that it can promote the increase of peripheral blood leukocyte count of mice injured by ionizing radiation, reduce the number of micronuclei of bone marrow cells, help the body repair the damage caused by ionizing radiation, and has the effect of reducing the harm of ionizing radiation.

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a pharmaceutical composition for alleviating the harm of ionizing radiation. Background Art

[0002] Ionizing radiation refers to radiation that carries enough energy to ionize atoms or molecules of matter, including cosmic rays, X-rays, and radiation from radioactive substances. There are two main sources of ionizing radiation: one is natural radiation, which comes from the universe and the air and water on the surface of the earth, as well as radioactive substances in the human body; the other is artificial radiation, including medical photoradiology, medical imaging, and radiotherapy. Systemic or local tissue damage caused by ionizing radiation is called ionizing radiation injury. The main source of ionizing radiation injury is radiotherapy for malignant tumors. While radiation kills tumor cells, it also causes certain damage to the surrounding normal tissues, causing radiation damage to multiple systems of the body, the most common of which is damage to the hematopoietic system and immune system, mainly bone marrow suppression, anemia and bleeding risks increase significantly, immune function decreases, leading to an increase in complications, and seriously affecting the quality of life of patients.

[0003] At present, Western medicine treatment for ionizing radiation damage mostly uses large doses of antibiotics and glucocorticoids, as well as chemically synthesized substances such as cysteamine, amifostine and estradiol, etc., which are not very effective and have great toxic side effects and cannot be used for a long time. In recent years, many scholars have found that traditional Chinese medicine can improve the quality of life of radiotherapy patients, prolong their survival, and have a good protective effect on the damage caused by radiotherapy. The combination of various Chinese medicines can regulate the spleen and stomach deficiency caused by radiotherapy and effectively prevent bone marrow suppression. It is reported that the Chinese medicine Shiquan Dabu Decoction (prescription ingredients: angelica, Chuanxiong, white peony, Rehmannia root, ginseng, Atractylodes macrocephala, Poria, roasted licorice, Astragalus, cinnamon), Bazhen Decoction (prescription ingredients: ginseng, Atractylodes macrocephala, white Poria, angelica, Chuanxiong, white peony, Rehmannia root, roasted licorice), Yangzheng Mixture (prescription ingredients: red ginseng, Astragalus, Lycium barbarum, Ligustrum lucidum, Polyporus, Poria), Buzhong Yiqi Decoction (prescription ingredients: Astragalus, roasted licorice, ginseng, angelica, tangerine peel, Cimicifuga, Bupleurum, Atractylodes macrocephala), Danggui Buxue Decoction (prescription ingredients: Astragalus, angelica), Liuwei Dihuang Pills (prescription ingredients: Rehmannia root, wine-boiled Cornus officinalis, peony bark, yam, Poria, Alisma) and others have good improvement and prevention and treatment effects on damage to the blood, genetic, immune and antioxidant systems caused by radiation. Some ingredients in traditional Chinese medicine, such as polysaccharides, alkaloids, saponins, volatile oils, coumarins, etc., can scavenge free radicals, promote granulocyte hematopoiesis, increase white blood cell count, enhance the body's immunity, and repair hematopoietic tissue damage.

[0004] From the perspective of TCM etiology, ionizing radiation can penetrate the skin, mouth, nose, and orifices to invade the human body, damage the internal organs, cause dysfunction of the internal organs, and imbalance of qi, blood, yin and yang. The induced pathological evolution process is consistent with the pathogenic characteristics of toxic evil, so it can be regarded as an external toxic evil. At the same time, ionizing radiation has high energy, strong pyrogenicity and penetrating power. When it works, it releases a large amount of energy, making the toxic evil have both hot and fiery qi. According to its action characteristics, it can be regarded as a kind of fire toxic evil and heat toxic evil. The basic pathogenesis is fire, stasis, and deficiency. The main cause of the disease is "deficiency of body fluid and blood, endogenous pathogenic heat, yin deficiency leads to excessive fire, and dryness and heat are unbearable". The fire-inducing soup recipe comes from Chen Shiduo's "Differentiation Record" in the Qing Dynasty. Its medicinal composition is: Rehmannia glutinosa, Morinda officinalis, Poria cocos, Ophiopogon japonicus, and Schisandra chinensis. Fire-inducing soup nourishes yin to reduce virtual fire and guides fire back to the origin to coordinate yin and yang. It is suitable for the phenomenon of yin deficiency and excessive fire with yin deficiency and endogenous yang heat. The applicant previously explored the mechanism of action of Yinhuo Decoction in preventing and treating ionizing radiation damage [Zhou Lihui, et al. Exploring the mechanism of action of Yinhuo Decoction in preventing and treating radiation damage based on network pharmacology [J]. Specialty Product Research, 2022, 44(4): 44-52.]. Summary of the invention

[0005] The present invention provides a pharmaceutical composition for reducing the harm of ionizing radiation, and aims to provide a pharmaceutical composition and a medicine for reducing ionizing radiation damage with clear ingredients and better effects. The present invention, through in-depth research on the Yinhuo Decoction, seeks its relevant effective ingredients, and develops a pharmaceutical composition for reducing ionizing radiation damage with clear ingredients and better effects. The application of the pharmaceutical composition and the medicine can effectively help the body repair the body damage caused by ionizing radiation and promote the body to recover as soon as possible; it can be used to reduce ionizing radiation damage and reduce the side effects of cancer radiotherapy.

[0006] The technical solution adopted by the present invention is: composed of the following components in parts by weight:

[0007] 570-630 parts of Rehmannia root, 4-14 parts of crystal orchid glycosides, 17-27 parts of nasturtium, 60-80 parts of Ophiopogon japonicus polysaccharides, 75-95 parts of Poria cocos polysaccharides, 1-5 parts of Pachymic acid, and 1-3 parts of Schisandrin.

[0008] The preparation method of the ophiopogon japonicus polysaccharide is as follows: pulverizing ophiopogon japonicus to obtain ophiopogon japonicus powder with a particle size of 120-180 mesh, soaking in water: the mass volume ratio of ophiopogon japonicus powder to water is 1:8-16, g / mL, the soaking time is 0.5-2h, decocting and extracting, the decocting temperature is 90-100°C, decocting 2-4 times, each decocting time is 0.5-2h, separating the filtrate, concentrating and drying to obtain the ophiopogon japonicus polysaccharide.

[0009] The drying is any one of conventional drying: freeze drying, vacuum drying, spray drying, boiling drying or microwave drying.

[0010] A method for preparing a pharmaceutical composition for reducing the hazards of ionizing radiation comprises the following steps:

[0011] (1) crushing Rehmannia glutinosa to obtain Rehmannia glutinosa powder, soaking it in water, decocting it for extraction, separating the filtrate, concentrating it, and drying it to obtain Rehmannia glutinosa extract;

[0012] (2) The Rehmannia glutinosa extract is mixed with the remaining components of the composition, including chloranthus glycosides, nastrin, ophiopogon japonicus polysaccharide, pachymannan, pachymic acid, and schisandra chinensis, to obtain a pharmaceutical composition.

[0013] In the step (1), the particle size of the Rehmannia glutinosa powder is sieved through a 5-20 mesh sieve, and the mass volume ratio of the Rehmannia glutinosa powder to water is 1:8-20, g / mL; after the Rehmannia glutinosa powder is mixed with water, it is soaked for 0.5-2h, decocted and extracted 2-4 times, each time for 1-2h, the extract is filtered, the filtrate is combined, and the filtrate is concentrated and dried to obtain the Rehmannia glutinosa extract.

[0014] The invention discloses an application of a pharmaceutical composition for alleviating the harm of ionizing radiation in preparing a drug for alleviating the harm of ionizing radiation.

[0015] A pharmaceutical composition for reducing the harm of ionizing radiation comprises the pharmaceutical composition and medically acceptable auxiliary materials; the dosage form of the drug is any one of pills, tablets, capsules, granules, mixtures or oral liquids in any pharmaceutically acceptable dosage form.

[0016] The medically acceptable excipients include starch, dextrin, sucrose, milk powder, sweeteners, mannitol, lactose, cellulose and its derivatives, calcium carbonate, cyclodextrin, β-cyclodextrin, phospholipid materials, magnesium stearate, talc, preservatives or flavors.

[0017] The beneficial effects of the present invention are:

[0018] 1. Based on the fire-inducing soup recipe, the present invention screens the Chinese medicinal ingredients and active ingredients of the recipe, and obtains the composition of the present invention containing Rehmannia glutinosa, crystal orchid glycosides, nastose, Ophiopogon japonicus polysaccharide, Poria cocos polysaccharide, Pachymic acid, and Schisandrin. The active ingredients cooperate with each other, which can help the body repair damage caused by ionizing radiation, promote the recovery of damaged hematopoietic system and immune system, increase the number of peripheral blood leukocytes and reduce the number of micronuclei of bone marrow cells. The pharmaceutical composition and its preparation can effectively prevent and reduce the harm of ionizing radiation, and are conducive to reducing the side effects of cancer radiotherapy.

[0019] 2. The present invention selects the main active ingredients from various medicinal materials, reasonably combines them, and works synergistically, which can effectively repair the body damage caused by ionizing radiation; the raw materials of the composition are prepared by the preferred extraction method, the active ingredient extraction rate is high, and the medicinal resources are fully utilized; the pharmaceutical composition is prepared by a specific method, the composition has clear ingredients, and the quality can be guaranteed to be stable and controllable, the efficacy is stable, which is conducive to promotion and application, and can be used to reduce side effects of tumor patients receiving radiotherapy, and reduce ionizing radiation damage from various sources. DETAILED DESCRIPTION

[0020] In order to further illustrate the features of the present invention, the following is further described in conjunction with specific embodiments. It should be noted that the following embodiments are only preferred embodiments of the present invention, not all. Based on the following embodiments, those skilled in the art can make various changes and modifications to the present invention according to the disclosed content, and they should also belong to the scope of protection claimed in the present invention. In the following embodiments, unless otherwise specified, the operating methods used are conventional operating methods, the equipment used are conventional equipment, the equipment materials used in each embodiment are the same, and the preparation method is conventional mixing. In the following embodiments, the raw materials used are all commercially available products, and the water used is all pure water.

[0021] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of the present invention.

[0022] When the embodiment gives a numerical range, it should be understood that, unless otherwise specified in the present invention, the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those of ordinary skill in the art to which the present invention belongs.

[0023] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. In the following examples and comparative examples, the crystal orchid glycoside (molecular formula C 16 H 22 O 11 , CAS No: 5945-50-6), Nesbitol (molecular formula C 24 H 42 O 21 , CAS No: 13133-07-8), Poria polysaccharide (CAS No: 65673-98-1), Pachymic acid (molecular formula C 33 H 52O5, CAS No: 29070-92-6), Schisandrin (molecular formula C 24 H 32 O7, CAS No: 7432-28-2), the Radix Rehmanniae glutinosae is the dried root of Radix Rehmanniae of Scrophulariaceae, and is a processed product prepared according to the processing method specified in the Chinese Pharmacopoeia. The specific processing method has no effect on the technical effect. Unless otherwise specified, the Radix Rehmanniae glutinosae used in the embodiments and comparative examples is a commercially available product. The Radix Ophiopogonis is the dried root of Radix Ophiopogonis of Liliaceae, which nourishes yin and produces body fluid, moistens the lungs and clears the heart, and is used for dry cough due to lung dryness, tuberculosis due to yin deficiency, sore throat due to throat numbness, thirst due to body fluid injury, internal heat and thirst, restlessness and insomnia, and constipation due to dry intestines.

[0024] In the following embodiment, the preparation method of the Ophiopogon japonicus polysaccharide is as follows: Ophiopogon japonicus is crushed, passed through a 120-mesh sieve to obtain Ophiopogon japonicus powder, mixed with 15 times the amount of water, soaked for 1 hour, decocted at 95-100°C, decocted 3 times, decocted for 1 hour each time to extract the active substance, separated the filtrate, concentrated and dried to obtain Ophiopogon japonicus polysaccharide.

[0025] Examples 1-5

[0026] A pharmaceutical composition for reducing the hazards of ionizing radiation, comprising the components in parts by weight as shown in Table 1:

[0027] Table 1 Components and their weights in Examples 1-5

[0028] Weight Example 1 Example 2 Example 3 Example 4 Example 5 Rehmannia root 600 570 630 600 600 Crystalline orchid 9 4 14 11 7 Nice sugar 22 17 27 26 18 Ophiopogon japonicus polysaccharide 70 60 80 70 70 Poria polysaccharide 85 75 95 80 90 Pachymic acid 3 1 5 2.4 3.6 Schisandrin 2 1 3 2 2

[0029] The method for preparing the pharmaceutical composition of Examples 1-5 comprises the steps of:

[0030] (1) Grinding Rehmannia glutinosa to obtain Rehmannia glutinosa powder, passing through a 20-mesh sieve, mixing with water, the volume ratio of Rehmannia glutinosa powder to water being 1:12, soaking for 1 hour, decocting and extracting 3 times, each time for 1.5 hours, filtering the extract, combining the filtrate, concentrating, and drying to obtain Rehmannia glutinosa extract;

[0031] (2) The Rehmannia glutinosa extract is mixed with the remaining components of the composition, including chloranthus glycosides, nastrin, ophiopogon japonicus polysaccharide, pachymannan, pachymic acid, and schisandra chinensis, to obtain a pharmaceutical composition.

[0032] Control extract: A control extract was prepared according to the original recipe of Yinhuo Decoction (3 liang of cooked rehmannia root, 1 liang of officinalis root and ophiopogon root, 2 qian of northern angelica root, and 5 qian of Poria cocos), and the following components were included by weight: 600 parts of cooked rehmannia root, 200 parts of officinalis root, 200 parts of ophiopogon root, 40 parts of northern angelica root, and 100 parts of Poria cocos. The above medicinal materials were crushed to obtain medicinal powder, passed through a 20-mesh sieve, mixed with water, the volume ratio of medicinal powder to water was 1:12, soaked for 1 hour, decocted and extracted 3 times, each time for 1.5 hours, the extract was filtered, the filtrate was combined, concentrated, and dried to obtain a control extract.

[0033] Comparative Example 1: The pharmaceutical composition comprises the following ingredients in parts by weight: 600 parts of Rehmannia glutinosa extract, 9 parts of astragaloside, 22 parts of nastrin, 70 parts of Ophiopogon japonicus polysaccharide, 85 parts of Poria cocos polysaccharide, 3 parts of pachymic acid, and 2 parts of schisandra chinensis.

[0034] The preparation method of the above pharmaceutical composition is the same as that of Example 1.

[0035] The difference from Example 1 is that the components of the pharmaceutical composition are changed, the crystal orchid glycoside in the pharmaceutical composition is replaced by astragaloside, and the remaining components, weight portions and preparation method of the pharmaceutical composition are the same as those in Example 1.

[0036] Comparative Example 2: The pharmaceutical composition comprises the following ingredients by weight: 600 parts of Rehmannia glutinosa extract, 9 parts of chloranthus glycosides, 22 parts of sucrose, 70 parts of fructose, 85 parts of pachymannan, 3 parts of pachymic acid, and 2 parts of schisandra chinensis. The preparation method of the pharmaceutical composition is the same as that of Example 1.

[0037] The difference from Example 1 is that the components of the pharmaceutical composition are changed, and nesitose, ophiopogon polysaccharide, and pachymannan in the pharmaceutical composition are replaced with sucrose, fructose, and pachymannan. The remaining components, weight portions, and preparation method of the pharmaceutical composition are the same as those in Example 1.

[0038] Comparative Example 3: The pharmaceutical composition comprises the following ingredients in parts by weight: 600 parts of Rehmannia glutinosa extract, 9 parts of chloranthus glycosides, 22 parts of nasturtium, 70 parts of Ophiopogon japonicus polysaccharides, 85 parts of Poria cocos polysaccharides, 3 parts of ferulic acid, and 2 parts of schisandra chinensis.

[0039] The difference from Example 1 is that the components of the pharmaceutical composition are changed, and the pachymic acid in the pharmaceutical composition is replaced by ferulic acid. The remaining components, weight portions and preparation method of the pharmaceutical composition are the same as those of Example 1.

[0040] Comparative Example 4: The pharmaceutical composition comprises the following ingredients in parts by weight: 600 parts of Rehmannia glutinosa extract, 9 parts of chloranthus glycosides, 22 parts of nasturtium, 70 parts of Ophiopogon japonicus polysaccharide, 85 parts of Poria cocos polysaccharide, 3 parts of Pachymic acid, and 2 parts of citric acid.

[0041] The difference from Example 1 is that the components of the pharmaceutical composition are changed, and the schisandra chinensis in the pharmaceutical composition is replaced by citric acid. The remaining components, weight portions and preparation method of the pharmaceutical composition are the same as those of Example 1.

[0042] Efficacy evaluation test

[0043] The present invention conducts an efficacy evaluation test of a pharmaceutical composition for alleviating the harm of ionizing radiation, observes the effect of the pharmaceutical composition of the present invention on ionizing radiation damage model animals, and evaluates its effect of alleviating ionizing radiation damage.

[0044] Experimental methods

[0045] Preparation methods of the pharmaceutical compositions and control extracts of Examples 1-5 and Comparative Examples 1-4:

[0046] 1. According to the weight of each component of Examples 1-5 and Comparative Examples 1-4 in Table 1, mix the compositions of Examples 1-5 and Comparative Examples 1-4 to make powders. Prepare the control extract according to the preparation method of the control extract and make it into powders. Before use, disperse the powder with an equal amount of distilled water, shake well when using, and store at 4°C. Evaluate the protective effect of the compositions of Examples 1-5, Comparative Examples 1-4, and the control extract on ionizing radiation damage.

[0047] 2. Experimental animals: Healthy SPF female mice from Kunming, weighing 18 g to 22 g, were used.

[0048] 3. Administration Method The pharmaceutical compositions and control extracts of Examples 1-5 and Comparative Examples 1-4 were administered at a dose of 1.2 g / kg. They were orally administered once a day for 28 consecutive days, then irradiated, and then the test substance was continued to be administered until the end of the experiment. The gavage volume of mice was 10 mL / kg BW. At the same time, the model control group (0 mL / kg BW) was set up with sterile water instead of the test substance, and the daily gavage volume was the same as that of each test substance group. Each group was given maintenance feed.

[0049] 4. Evaluation test items

[0050] 4.1 Peripheral blood leukocyte count experiment: The test sample group was orally administered the test sample continuously before and after irradiation. The dose group and the model control group were irradiated with the same dose of γ-rays once. The irradiation dose was 3.0 Gy (absorbed dose rate 1.0 Gy / 60s, time 3 min). 20 μL of peripheral blood was collected three times before irradiation, on the 3rd day after irradiation, and on the 14th day after irradiation, and added to 0.38 mL of 1% hydrochloric acid. After mixing, it was added to the blood cell counting plate to calculate the total number of white blood cells in the four large squares in the counting pool.

[0051] 4.2 Mouse bone marrow cell micronucleus experiment: The dose group was orally administered with the test sample continuously before and after irradiation. The dose group and the radiation model control group were irradiated with the same dose of gamma rays once. The irradiation dose was 3.0Gy (absorbed dose rate 1.0Gy / 60s, time 3min). On the third day after irradiation, the animals were killed by cervical dislocation, the sternum was taken, the bone marrow fluid was squeezed out with hemostatic forceps and mixed with calf serum at one end of the glass slide, and a conventional smear was made. After the smear dried naturally, it was fixed in methanol for 10min, placed in Giemsa application dye solution, stained for 15min, immediately rinsed with distilled water, and dried. Under microscopic examination, the number of micronucleated cells in 1000 polychromatic erythrocytes of each animal was counted, and the micronucleus rate was expressed in per thousand.

[0052] 5. Statistical Analysis

[0053] The statistical software SPSS29.0 was used to perform statistical analysis on the experimental data of various indicators. The data results were expressed as mean ± standard deviation. The comparison among the groups was performed by one-way analysis of variance (ANOVA), and the pairwise comparison was performed by LSD method. The difference was considered statistically significant when p < 0.05.

[0054] 2. Results

[0055] 1. The results of the peripheral blood leukocyte count experiment are shown in Table 2:

[0056] Table 2 Effects of X-ray irradiation on the number of peripheral blood leukocytes in mice (n=10, )

[0057]

[0058] Note: Compared with the blank group, * : p<0.05, ** :p<0.01; compared with the model group, # : p<0.05, ## : p<0.01; compared with Example 1, ★: p<0.05, ★★: p<0.01; compared with Example 2, ※: p<0.05, ※※: p<0.01; compared with Example 3, ☆: p<0.05, ☆☆: p<0.01; compared with Example 4, ◇: p<0.05, ◇◇: p<0.01; compared with Example 5, ◆: p<0.05, ◆◆: p<0.01

[0059] 2. The results of the mouse bone marrow cell micronucleus experiment are shown in Table 3:

[0060] Table 3 Effects of X-ray irradiation on the micronucleus rate of bone marrow cells in mice (n=10, )

[0061]

[0062]

[0063] Note: Compared with the blank group, * : p<0.05, ** :p<0.01; compared with the model group, # : p<0.05, ## : p<0.01;

[0064] Compared with Example 1, ★: p<0.05, ★★: p<0.01; compared with Example 2, ※: p<0.05, ※※: p<0.01; compared with Example 3, ☆: p<0.05, ☆☆: p<0.01; compared with Example 4, ◇: p<0.05, ◇◇: p<0.01; compared with Example 5, ◆: p<0.05, ◆◆: p<0.01

[0065] Conclusion

[0066] In the comparative examples 1-4, the components in the composition are replaced with other components in turn. Since Astragalus has a good protective effect on the damage caused by radiotherapy, the main active ingredient astragaloside in Astragalus is used in comparative example 1 to replace the crystal orchid glycoside in Morinda officinalis. The experimental results show that the effect of comparative example 1 is not as good as that of the embodiment, and is equivalent to that of the control example. Because nesitose is sucrose tetrasaccharide, and the monosaccharide types of Ophiopogon japonicus polysaccharide are mainly fructose and glucose, fructose and sucrose are used to replace nesitose and Ophiopogon japonicus polysaccharide in comparative example 2, and Poria cocos polysaccharide, which is also a component of Poria cocos, is used to replace Poria cocos polysaccharide. The experimental results show that the effect of comparative example 2 is not as good as that of the embodiment, and is equivalent to that of the control example. Angelica sinensis has a blood-tonifying effect and is also an important component of Chinese patent medicines for radiotherapy such as Shiquan Dabu Decoction and Bazhen Decoction. Ferulic acid is an indicator component of Angelica sinensis. Ferulic acid is used to replace Poria cocos acid in comparative example 3. The experimental results show that the effect of comparative example 3 is not as good as that of the embodiment, and is equivalent to that of the control example. The active compounds in Schisandra chinensis mainly include two types of components, one is lignin compounds (schisandrin, etc.), and the other is organic acids (mainly citric acid, malic acid, etc.). Therefore, citric acid is used instead of schisandrin in Comparative Example 4. The experimental results show that the effect of Comparative Example 4 is not as good as that of the embodiment, and is equivalent to that of the reference example. Overall, the effect of the embodiment is worse than the control extract and the comparative example prepared according to the fire-inducing soup recipe, and the effects of the comparative example and the control extract are equivalent. The effects of Comparative Examples 1-4 in reducing damage to the body of irradiated mice are all lower than those of the embodiments, indicating that each component in the pharmaceutical composition of the present invention is the best choice.

[0067] The pharmaceutical composition of the present invention has the effect of reducing the harm of ionizing radiation; it can effectively promote the recovery of the blood system, increase the number of peripheral blood leukocytes of irradiated mice, reduce the number of micronuclei of bone marrow cells, and reduce the damage to the chromosomes of the body. The pharmaceutical composition of the present invention has clear ingredients, reasonable compatibility, and optimal efficacy.

[0068] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A pharmaceutical composition for reducing the hazards of ionizing radiation, characterized in that: It is composed of the following components by weight: 570-630 parts of Rehmannia root, 4-14 parts of crystal orchid glycosides, 17-27 parts of nasturtium, 60-80 parts of Ophiopogon japonicus polysaccharides, 75-95 parts of Poria cocos polysaccharides, 1-5 parts of Pachymic acid, and 1-3 parts of Schisandrin.

2. A pharmaceutical composition for reducing the hazards of ionizing radiation according to claim 1, characterized in that: The preparation method of the ophiopogon japonicus polysaccharide is as follows: pulverizing ophiopogon japonicus to obtain ophiopogon japonicus powder with a particle size of 120-180 mesh, soaking in water: the mass volume ratio of ophiopogon japonicus powder to water is 1:8-16, g / mL, the soaking time is 0.5-2h, decocting and extracting, the decocting temperature is 90-100°C, decocting 2-4 times, each decocting time is 0.5-2h, separating the filtrate, concentrating and drying to obtain the ophiopogon japonicus polysaccharide.

3. A pharmaceutical composition for reducing the hazards of ionizing radiation according to claim 2, characterized in that: The drying is any one of conventional drying: freeze drying, vacuum drying, spray drying, boiling drying or microwave drying.

4. The method for preparing the pharmaceutical composition according to any one of claims 1 to 3, characterized in that: The following steps are involved: (1) crushing Rehmannia glutinosa to obtain Rehmannia glutinosa powder, soaking it in water, decocting it for extraction, separating the filtrate, concentrating it, and drying it to obtain Rehmannia glutinosa extract; (2) The Rehmannia glutinosa extract is mixed with the remaining components of the composition, namely, nysitose, ophiopogon japonicus polysaccharide, pachymannan, pachymic acid, and schisandra chinensis, to obtain a pharmaceutical composition.

5. The preparation method according to claim 4, characterized in that: In the step (1), the particle size of the Rehmannia glutinosa powder is sieved through a 5-20 mesh sieve, and the mass volume ratio of the Rehmannia glutinosa powder to water is 1:8-20, g / mL; after the Rehmannia glutinosa powder is mixed with water, it is soaked for 0.5-2h, boiled and extracted 2-4 times, each time for 1-2h, the extract is filtered, the filtrate is combined, and the filtrate is concentrated and dried to obtain the Rehmannia glutinosa extract.

6. Use of the pharmaceutical composition according to any one of claims 1 to 3 in the preparation of a drug for reducing the hazards of ionizing radiation.

Images